Compare · ELV vs GTH
ELV vs GTH
Side-by-side comparison of Elevance Health Inc. (ELV) and Genetron Holdings Limited (GTH): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ELV and GTH operate in Medical Specialities (Health Care), so they compete in similar markets.
- ELV is the larger of the two at $82.26B, about 262.2x GTH ($313.7M).
- ELV has hit the wire 6 times in the past 4 weeks while GTH has been quiet.
- ELV has more recent analyst coverage (23 ratings vs 0 for GTH).
- Company
- Elevance Health Inc.
- Genetron Holdings Limited
- Price
- $376.48-0.75%
- $4.02+0.00%
- Market cap
- $82.26B
- $313.7M
- 1M return
- -1.95%
- -
- 1Y return
- +34.27%
- -
- Industry
- Medical Specialities
- Medical Specialities
- Exchange
- NYSE
- NASDAQ
- IPO
- 2020
- News (4w)
- 6
- 0
- Recent ratings
- 23
- 0
Elevance Health Inc.
Elevance Health Inc. operates as a health benefits company. It supports consumers, families, and communities across the entire care journey connecting to the care, support, and resources to lead healthier lives. It serves approximately 118 million people through a portfolio of medical, digital, pharmacy, behavioral, clinical, and care solutions. The company was formerly known as Anthem, Inc. and changed its name to Elevance Health Inc. in June 2022. Elevance Health Inc. was founded in 1944 and is headquartered in Indianapolis, Indiana.
Genetron Holdings Limited
Genetron Holdings Limited, a precision oncology company, engages in the cancer molecular profiling, and harnessing technologies in molecular biology and data science for cancer treatment. The company offers diagnosis and monitoring services, and early liver cancer screening services through laboratory developed tests services, such as HCCscreen, a proprietary assay for the early screening of hepatocellular carcinoma. It also provides in-vitro diagnostic products, including 8-gene lung cancer assay, an IVD assay product based on semiconductor sequencing to detect lung cancer; Genetron 3D biochip reading instrument; IDH1 and TERT gene assays for glioma; Genetron S5 platform, a semiconductor-based NGS system, which detects the nucleotide through detecting the change in pH; and Genetron S2000 platform, a production-scale sequencer. In addition, the company develops ctDNA lung cancer assay for mutations in the epidermal growth factor receptor gene. Further, it offers development services in the areas of genomics research and clinical development in collaboration with biopharmaceutical companies, hospitals, and research institutions worldwide. The company has a strategic partnership with JD Health to create solutions for full-cycle cancer management. Genetron Holdings Limited was founded in 2015 and is headquartered in Beijing, the People's Republic of China.
Latest ELV
- Director Peru Ramiro G bought $366,050 worth of shares (1,000 units at $366.05), increasing direct ownership by 10% to 10,908 units (SEC Form 4)
- President and CEO Boudreaux Gail bought $1,002,230 worth of shares (2,725 units at $367.79), increasing direct ownership by 2% to 171,976 units (SEC Form 4)
- SEC Form 10-Q filed by Elevance Health Inc.
- Elevance Health Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Elevance Health Reports Second Quarter 2026 Results; Raises Full-Year Guidance
- Elevance Health to Hold Conference Call and Webcast to Discuss Second Quarter 2026 Results on July 15, 2026
- New Elevance Health Public Policy Institute Study Examines Payment Disputes for Planned Procedures Under the No Surprises Act
- Thomas Carr Howe Middle School Unveils New Fitness and Strength Training Space Through Partnership with Elevance Health and Impact Fitness Foundation
- Elevance Health Makes Clinical Review Faster, More Connected with Health OS
- SEC Form 11-K filed by Elevance Health Inc.
Latest GTH
- SEC Form 15-12G filed by Genetron Holdings Limited
- SEC Form SC 13D/A filed by Genetron Holdings Limited (Amendment)
- SEC Form SC 13D/A filed by Genetron Holdings Limited (Amendment)
- SEC Form SC 13D/A filed by Genetron Holdings Limited (Amendment)
- SEC Form SC 13D/A filed by Genetron Holdings Limited (Amendment)
- SEC Form S-8 POS filed by Genetron Holdings Limited
- SEC Form 25-NSE filed by Genetron Holdings Limited
- SEC Form SC 13E3/A filed by Genetron Holdings Limited (Amendment)
- Genetron Health Announces Completion of Going Private Transaction
- SEC Form 6-K filed by Genetron Holdings Limited